USP2 Antibody (YA7057)
(Synonyms: 41 kDa ubiquitin specific protease antibody; 41 kDa ubiquitin-specific protease antibody; Deubiquitinating enzyme 2 antibody; Ubiquitin carboxyl terminal hydrolase 2 antibody; Ubiquitin carboxyl-terminal hydrolase 2 antibody; ubiquitin specific peptidase 2 antibody; Ubiquitin specific processing protease 2 antibody; Ubiquitin specific protease 12 antibody; Ubiquitin specific protease 9 antibody; Ubiquitin specific protease, 41kD antibody)USP2 Antibody (YA7057) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to USP2.
-
Host:
Mouse
-
Isotype:
IgG
-
Application:
WB
-
Reactivity :
Human
-
Formulation:
Supplied in 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
WB
WB: Western Blot
|
|---|---|
| Dilution Ratio | 1:1000-2000 |
Product Details
USP2 Antibody (YA7057) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to USP2.
-
Host Mouse
-
Clonality Monoclonal
-
Species ReactivityHuman
-
Observed Molecular WeightObserved band size: 68 kDa
Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 68 kDa
Recombinant human USP2 1-258aa.
Endogenous
Protein G affinity purified.
Non-conjugated
Unmodified
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
USP2 is a ubiquitin-specific deubiquitinase that regulates protein ubiquitination, protein stability, and cellular proteostasis[1][2]. Mechanistically, USP2 connects ubiquitin-proteasome signaling with cell survival, cell cycle control, circadian rhythm, metabolism, inflammation, antiviral response, and metastasis through substrates including Cyclin D1, PER1, CRY1, HDM2/p53, FASN, LDLR, TRAF6, TBK1, and TGFBR complexes[1]. In disease models, USP2 elevation has been reported in glioma, testicular cancer, breast cancer, prostate cancer, inflammatory diseases, and hepatocellular carcinoma models[1][3]. Compared with related isoforms, USP2a and USP2b show distinct biological roles: USP2a attenuates diabetes in adipose tissue macrophages, whereas USP2b aggravates type 2 diabetes and metabolic dysfunction-associated steatotic liver disease in hepatocytes[4]. In hepatocellular carcinoma, USP2 stabilizes PPARγ, promotes fatty-acid biosynthesis and oleic acid production, and supports M2 macrophage polarization[5]. For experimental applications, ML364 showed anticancer responses against HCC patient-derived organoids, while current USP2 inhibitors remain unapproved clinically and require improved specificity[1][5].
-
Subcellular Localization
Cytoplasm,Cytoplasm, perinuclear region,Nucleus,Membrane,Cytoplasm
-
Expression
Tissue_Specificity: Expressed in mesangial cells of the kidney and in different types of glomerulonephritides (at protein level)
Induction: Down-regulated by cisplatin (at protein level) -
Isoforms & Post-Translational Modification
O75604 has four isomers: O75604-1: 68072 Da (predicted); O75604-2: 40638 Da (predicted); O75604-3: 41682 Da (predicted); O75604-4: 45241 Da (predicted).
-
Subunit
Homooligomer (By similarity)
-
SwissProt ID
-
Synonyms
41 kDa ubiquitin specific protease antibody; 41 kDa ubiquitin-specific protease antibody; Deubiquitinating enzyme 2 antibody; Ubiquitin carboxyl terminal hydrolase 2 antibody; Ubiquitin carboxyl-terminal hydrolase 2 antibody; ubiquitin specific peptidase 2 antibody; Ubiquitin specific processing protease 2 antibody; Ubiquitin specific protease 12 antibody; Ubiquitin specific protease 9 antibody; Ubiquitin specific protease, 41kD antibody
Documentation
[2]. Xian Y, et al. Deubiquitinases as novel therapeutic targets for diseases. MedComm (2020). 2024 Dec 13;5(12):e70036. [Content Brief]
[4]. Kitamura H, et al. Ubiquitin-Specific Protease 2 (USP2) as a Modulator of Energy Metabolism: A Review of Studies Using Animal and Cellular Models. Biomedicines. 2026 Mar 30;14(4):783. [Content Brief]
[5]. Cao J, et al. USP2-mediated PPARγ stabilization promotes hepatocellular carcinoma progression and M2 macrophage polarization via oleic acid. J Immunother Cancer. 2025 Nov 4;13(11):e012721. [Content Brief]
Powered by Bioz
